Jean-Charles Fruchart

发表

Sorting out the roles of PPARα in energy metabolism and vascular homeostasis

Philippe Lefebvre, B. Staels, J. Fruchart, 2006 .

FXR‐deficiency confers increased susceptibility to torpor

Folkert Kuipers, R. Burcelin, B. Staels, 2007, FEBS letters.

Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.

Len A Pennacchio, Bryan Brewer, L. Pennacchio, 2004, Biochemical and biophysical research communications.

Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–&agr; Activators: Clinical and Experimental Evidence

Alberto Zambon, B. Staels, P. Pauletto, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Postprandial Dyslipidemia: A Risk Factor for Coronary Heart Disease

J. Dallongeville, J. Fruchart, Jean Dallongeville, 1998, Annals of Nutrition and Metabolism.

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.

Nikolaus Marx, Takashi Kadowaki, Alberto Zambon, 2008, The American journal of cardiology.

Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor α Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein β*

Robert Kleemann, Teake Kooistra, T. Kooistra, 2001, The Journal of Biological Chemistry.

Characterization of a new mouse model for human apolipoprotein A-I/C-III/A-IV deficiency Published, JLR Papers in Press, February 23, 2006.

N. Maeda, G. Torpier, J. Fruchart, 2006, Journal of Lipid Research.

Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.

Fulvio Loiodice, Vincenzo Tortorella, Ettore Novellino, 2005, Journal of medicinal chemistry.

Measurement of arterial wall thickness as a surrogate marker for atherosclerosis.

A. Smit, J. Kastelein, J. Fruchart, 2004, Circulation.

Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat

Robert L. Wolff, J. Dallongeville, B. Staels, 1999, Lipids.

The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice*

Folkert Kuipers, A. Grefhorst, F. Gonzalez, 2006, Journal of Biological Chemistry.

Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.

B. Staels, J. Fruchart, C. Duval, 2003, Molecular endocrinology.

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

J. Fruchart, Jean-Charles Fruchart, 2013, Cardiovascular Diabetology.

The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition*

Folkert Kuipers, A. Grefhorst, F. Gonzalez, 2005, Journal of Biological Chemistry.

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity*

Bruno Derudas, Timothy M. Willson, L. Madsen, 2000, The Journal of Biological Chemistry.

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1*

Frank J. Gonzalez, G. Haegeman, J. Peters, 1999, The Journal of Biological Chemistry.

Atherogenic Lipoprotein Particles in Atherosclerosis

J. Fruchart, P. Duriez, R. Carmena, 2004, Circulation.